EYPT News and Press, EyePoint Pharmaceuticals Inc. From 03/02/23

EyePoint Pharmaceuticals ( NASDAQ: EYPT ) stock fell ~8% on Thursday after the company reported its Q4 results. Net loss widened to -$43.45M, compared to -$19.43M in Q4 2021. Meanwhile, total revenue in Q4 declined -8.7% Y/Y to $10.53M, but did manage to beat analysts expectat...

EyePoint Pharmaceuticals press release ( NASDAQ: EYPT ): Q4 GAAP EPS of -$1.16 misses by $0.54 . Revenue of $10.53M (-8.8% Y/Y) beats by $0.13M . Cash, cash equivalents and investments in marketable securities on December 31, 2022 totaled $144.6M. We expect the cas...

– Phase 2 DAVIO 2 clinical trial in wet AMD on track with topline data anticipated by year-end 2023 – – Phase 2 PAVIA clinical trial in non-proliferative diabetic retinopathy (NPDR) on track with enrollment completion anticipated in 4Q 2023 – –...

EyePoint Pharmaceuticals ( NASDAQ: EYPT ) is scheduled to announce Q4 earnings results on Thursday, March 2nd, before market open. The consensus EPS Estimate is -$0.62 (-5.1% Y/Y) and the consensus Revenue Estimate is $10.4M (-9.9% Y/Y). Over the last 3 months, EPS estimates h...

Rallybio ( NASDAQ: RLYB ) and EyePoint Pharmaceuticals ( NASDAQ: EYPT ) are in a research collaboration evaluating delivery of the former's complement component 5 (C5) inhibitor using the latter's Durasert technology for intraocular drug delivery. The beginning focus ...

WATERTOWN, Mass. and NEW HAVEN, Conn., Feb. 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, and Rallybio Corporation, a clinical-stage biotec...

WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a conference call and...

Summary Ocular Therapeutix is a promising platform play poised to disruptively transform ophthalmology. Based on its innovative and validated hydrogel platform, Ocular can fill and expand its pipeline with unlimited new applications. With Dextenza, Ocular has an approved and profitable ...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - January 31, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - January 24, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is...